Welcome to our dedicated page for Wellgistics Health news (Ticker: WGRX), a resource for investors and traders seeking the latest updates and insights on Wellgistics Health stock.
Wellgistics Health, Inc. (NASDAQ: WGRX) generates news at the intersection of pharmacy distribution, health information technology, artificial intelligence, and blockchain-enabled smart contracts. Company announcements highlight how its integrated platform connects more than 6,500 pharmacies and over 200 manufacturers, combining wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services.
Recent news has focused on the rollout and evolution of the EinsteinRx™ pharmacy dispensing optimization AI platform, including its integration into pharmacy point-of-sale systems and its role as a prescription management hub. Updates also cover the development of the PharmacyChain™ blockchain-enabled smart contracts platform, supported by a license agreement with DataVault AI Inc. and the use of tokenization and quantum key encryption to create secure digital twins of pharmacy processes and transactions.
Investors and industry observers can follow coverage of therapeutic and product initiatives such as the commercial launch of the diabetes drug Brenzavvy® through the Wellgistics Pharmacy Network, distribution of GLP-1 companion muscle loss medical foods with Tollo Health, and offerings related to Long COVID, including Galectovid™ and Tollovid®. News items also address corporate developments like letters of intent for acquisitions, sponsorship of Dream Bowl 2026 and related meme coin distributions, financial results, and Nasdaq listing compliance updates.
This news feed aggregates these disclosures so readers can review earnings-related releases, product and partnership announcements, regulatory filings referenced in press releases, and strategic updates about Wellgistics Health’s role in the U.S. prescription drug and wellness markets. Regularly reviewing this page can help users understand how the company’s AI, blockchain, and distribution capabilities are being applied across its pharmacy network and manufacturer relationships.
Wellgistics Health (NASDAQ:WGRX) released a shareholder letter outlining the strategy behind recently announced transactions that support a vertically integrated, blockchain-based healthcare data platform.
Key elements include DelivMeds AI and an expanded Datavault license, the QOLPOM patent portfolio, a controlling interest in Tollo Health, Forzet™, and a planned share restructuring with a new CUSIP.
Management argues that combining data tokenization, biometric verification, and direct patient engagement across 6,500 pharmacies and 200+ manufacturers positions Wellgistics as potential core healthcare infrastructure over the next decade.
Wellgistics Health (NASDAQ:WGRX)/b) shared a strategic update tied to a binding term sheet with Datavault AI to integrate the EinsteinRx AI dispensing platform into PharmacyChain, its blockchain smart-contract system.The letter details planned vertical integration moves, including DelivMeds AI, QOLPOM patents, Tollo Health, Forzet, and a planned share restructuring with a new CUSIP.
Wellgistics Health (NASDAQ:WGRX) approved a 1-for-50 reverse stock split of its common stock, effective 12:01 a.m. ET on May 26, 2026. The move is intended to raise the share price and help regain compliance with Nasdaq’s minimum bid requirement.
The split will reduce outstanding shares from about 125.7 million to about 2.5 million, with fractional shares rounded up, while authorized share counts and economic rights under options, warrants, and convertibles are proportionally adjusted.
Datavault AI (NASDAQ:DVLT) and Wellgistics Health (NASDAQ:WGRX) signed a fully binding term sheet to form DelivMeds AI (ticker reserved: NASDAQ:MEDS) via three concurrent transactions.
The structure includes a PharmacyChain™ HaaS license expansion, acquisition of QOLPOM biometric and drone logistics IP, and a controlling stake in Tollo Health, with an expected combined asset value of about $4 billion, subject to an independent fairness opinion and customary closing conditions.
Wellgistics Health (NASDAQ:WGRX) reported Q1 2026 results and a business update. Wellgistics Pharmacy monthly revenue rose from about $0.1M in November 2025 to $0.6M in April 2026. Sequential revenue increased from $0.486M in Q4 2025 to $0.929M in Q1 2026, with Q2 2026 revenue projected at $1.775M.
The company completed a Kare Pharmtech joint venture, gaining telepharmacy access to 200,000+ patient lives, and expanded its Tollo Health partnership, targeting an August 2026 “Health Lives Here” app launch with NFL Alumni Health. Net operating loss narrowed to $7.742M from $32.430M year over year.
Wellgistics Health (NASDAQ:WGRX) announced it will release first quarter 2026 financial results on Tuesday, May 19, 2026.
The healthcare technology and pharmaceutical distribution company will provide its Q1 2026 financial update to investors on that date.
Wellgistics Health (NASDAQ:WGRX) signed a non-binding LOI to acquire WellCare Today, a chronic care RPM, RTM and CCM provider, in a deal valued at about $15 million, including $3 million cash and a performance-based preferred stock earnout.
The planned acquisition would integrate WellCare Today's Samsung Galaxy Watch-based HealthAssist remote monitoring platform with Wellgistics' MSO pilot and a network of 6,500+ independent pharmacies to support Medicare-reimbursable RPM, RTM and CCM programs, aiming to expand clinical service and revenue opportunities, though reimbursement and deal completion are not assured.
Wellgistics Health (NASDAQ:WGRX) announced a pilot collaboration with Kare PharmTech and Kare Clinicals to integrate its MSO infrastructure for chronic care management (CCM) and remote patient monitoring (RPM) across multiple provider offices.
The U.S. RPM market is cited at $14 billion, projected to reach ~$29 billion by 2030 at a 12.6% CAGR. The pilot has generated 1,500+ claims to date and is intended as a base for broader provider expansion. Wellgistics plans to leverage its network of 6,500+ independent pharmacies to help identify eligible patients and support engagement, while participating pharmacists may gain access to new clinical service revenue opportunities.
Wellgistics Health (NASDAQ:WGRX) executed a definitive joint venture agreement with Kare PharmTech's Kare Rx Hub on April 14, 2026, combining technology and operations to accelerate pharmaceutical access, fulfillment, and commercialization.
The integrated ecosystem merges Wellgistics' EinsteinRx™ and HubRx AI™ with KareRx digital capabilities, aims to streamline eligibility, prior authorization, routing and direct-to-patient fulfillment, and claims potential reach to 200,000+ patient lives. The transaction formalizes a prior LOI, is subject to customary implementation steps, and additional details will be disclosed in a Form 8-K.
Wellgistics Health (NASDAQ:WGRX) signed a non-exclusive, non-binding $105,000,000 Letter of Intent dated March 23, 2026 to evaluate a potential all-stock acquisition of Neuritek Therapeutics, a neuroscience-focused research organization.
The proposed deal aims to expand Wellgistics' pharmacy distribution and AI-driven patient access platform by adding research and drug-development capabilities; it remains subject to due diligence, definitive agreements, board approvals, and customary closing conditions with no assurance of completion.